Friday, 16 October 2026European Markets

KEYWARE TECH. Stock Went Down By Over 17% So Far On Wednesday

Loading stream...

(VIANEWS) - Shares of KEYWARE TECH. (BEL 20: KEYW.BR) dropped by a staggering 17.48% to €0.85 at 11:21 EST on Wednesday, after five sequential sessions in a row of losses. BEL 20 is dropping 0.33% to €3,804.66, after three sequential sessions in a row of gains. This seems, as yet, a somewhat bearish trend trading session today.

KEYWARE TECH.'s last close was €0.98, 14.78% under its 52-week high of €1.15.

About KEYWARE TECH.

Keyware Technologies NV, an independent fintech company, provides electronic payment solutions in Belgium. It offers payment transaction software for banks and financial institutions, tokenization software, instalment payment solutions, and ordering and payment app software; and payment processing and management services, as well as engages in the rental and sale of payment terminals. The company was incorporated in 1996 and is headquartered in Zaventem, Belgium.

Earnings Per Share

As for profitability, KEYWARE TECH. has a trailing twelve months EPS of €0.05.

PE Ratio

KEYWARE TECH. has a trailing twelve months price to earnings ratio of 17. Meaning, the purchaser of the share is investing €17 for every euro of annual earnings.

The company's return on equity, which measures the profitability of a business relative to shareholder's equity, for the twelve trailing months is 2.37%.

Moving Average

KEYWARE TECH.'s value is way below its 50-day moving average of €1.01 and way under its 200-day moving average of €1.02.

Revenue Growth

Year-on-year quarterly revenue growth grew by 27.9%, now sitting on 17.69M for the twelve trailing months.

Volume

Today's last reported volume for KEYWARE TECH. is 3 which is 99.84% below its average volume of 1899.

Yearly Top and Bottom Value

KEYWARE TECH.'s stock is valued at €0.85 at 11:21 EST, way under its 52-week high of €1.15 and higher than its 52-week low of €0.81.

More news about KEYWARE TECH. (KEYW.BR).

What we know · the intelligence behind this page
Live from the substrate
What we're seeing
Q4 2026 Biopharma Catalyst Cluster: Late-Stage Readouts and Regulatory Milestones
October 2026 brings a dense run of Phase 3 wins (ALOFT-IPF, RESTORE-3), new data presentations (Roche, Bayer, Lilly, Vertex, Galderma) and regulatory steps (FDA acceptance of Roche's vamikibart BLA, Scholar Rock's EMA resubmission). The next big catalyst is the ivonescimab FDA PDUFA date on 2026-11-14. Obesity combination studies (REDEFINE 4, TOGETHER-PsO) and the 2027 Maritime-1 completion point to more catalysts ahead. QAIAx's speculative AI-linked trial claims (the QIII pilot, targeted for 2027) are an unrelated micro-cap sideshow with weak evidence, and have little in common with the large-cap pipeline news.
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
ING Group
Both facts record the same metric (shares_outstanding) for ING Group at the identical observation date (2025-12-31). FACT A states 2,902,437,688 shares; FACT B states 2,902 million shares (2,902,000,000). The difference is 437,688 shares (~0.015%). This is a genuine value conflict, though the discrepancy appears to result from FACT B rounding to the nearest million while FACT A provides the precise count.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,986
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,986 facts checked against source5,378 source documents archived
Query this data → isubstrate.com